Ogris lab

Master’s Thesis Opportunity

Molecular mechanism of the “PP2A-activating” anti-cancer drug DT-061
Is Protein Phosphatase 2A indeed the prime target of the anti-cancer drug DT061?

Open since Apr 08, 2026

About the lab

The Ogris Lab is dedicated to uncovering the mechanisms of Protein Phosphatase 2A (PP2A) biogenesis in eukaryotic cells. We are currently seeking a talented and motivated Master's student to join us in a project aimed at understanding the molecular mechanism of DT-061, an anti-cancer drug, proposed to exert its anti-cancer activity by acting as a small-molecule activator of specific PP2A holoenzymes.

 

About the project

PP2A comprises a large family of trimeric holoenzymes, each of which consist of a catalytic C (PP2Ac), a structural A (PP2Aa) and a regulatory, substrate-targeting B-type subunit. PP2A dysfunction has been implicated in numerous cancer types, contributing to uncontrolled cell growth and tumor progression. Therefore, targeting and restoring PP2A activity holds promise as a potential therapeutic strategy for cancer treatment. The assembly of PP2A trimers with tumor-suppressive functions is regulated by the reversible methylation of the PP2A catalytic subunit. A small molecule compound (SMAP), was reported to restore PP2A’s tumor-suppressive role by enhancing methylation and stabilizing PP2A-B56α complexes, leading to tumor cell death. However, cells lacking the PP2A methyltransferase or the targeted PP2A holoenzyme were not resistant to DT-061 and died at similar drug concentration as wild-type cells. Interestingly, DT-061 lead to the destruction of mitochondria, alterations of the Golgi and ER organelles and apoptotic cell death.

The project’s main goal is to decipher the mechanism how the anti-cancer drug DT-061 affects Mitochondria, Golgi and ER. In the frame of this project, you will gain expertise in the following techniques: mammalian tissue culture, cell metabolic assays, fluorescent activated cell sorting, protein analysis methods like, western blotting, immunoprecipitation, quantitative western blot and immunofluorescence analysis, DNA modification with CRISPR/Cas9.

The Master’s thesis will be carried out in the Ogris Lab at the Max Perutz Labs. The start date is preferably May 2026 for the duration of 10-12 months. The student will receive a stipend of about € 550,- per month.

 

Application and contact

Please send your CV and motivation letter to egon.ogris@meduniwien.ac.at and ingrid.frohner@meduniwien.ac.at until April 19, 2026.
You can find more details on the research topics on the page of the Ogris Lab.  

 

Download this ad as pdf

 

Back to Overview
11